Wiernik G, Alcock C J, Bates T D, Brindle J M, Fowler J F, Gajek W R, Goodman S, Haybittle J L, Henk J M, Hopewell J W
Br J Radiol. 1991 Mar;64(759):232-41. doi: 10.1259/0007-1285-64-759-232.
The second British Institute of Radiology trial of dose fractionation in radiotherapy compared two groups of prospectively randomized patients with squamous carcinoma of the laryngo-pharynx; one group was treated in a short (less than or equal to 4 weeks) and the other in a long (greater than 4 weeks) overall time. Treatment in any one centre could be given, with no planned gap in the course of treatment, either as a conventional, daily (5 fractions per week regime) or as 3 fractions per week. A total of 611 patients were allocated to treatment, of whom nine have had to be excluded from the analysis for a lack of information. Patients were admitted to the trial from January 1976 to December 1985 and were followed up for a maximum of 10 years and a minimum of 3 years. A reduction in total dose was made for use in the short compared with the long treatment regime. This reduction in total dose varied between 18% and 22% depending on whether 5 fractions or 3 fractions per week regimes were used. Overall, no statistically significant differences have been found between the two arms of the trial. The patients treated with 5 fractions per week in a short overall treatment time showed fewer late normal tissue effects. An analysis based on stratification by age, stage and anatomical site gave a relative risk (short/long overall treatment time) for deaths of 1.23 with a 95% confidence interval from 0.96 to 1.59. Analyses stratified for stage and site gave relative risks with 95% confidence intervals of 1 x 10 (0.84-1.44) for local recurrences/tumour persistence, and 1.01 (0.70-1.45) for laryngectomies.
英国放射学会开展的第二项放射治疗剂量分割试验,比较了两组前瞻性随机分组的喉咽鳞状细胞癌患者;一组接受短疗程(小于或等于4周)治疗,另一组接受长疗程(大于4周)治疗。任何一个中心的治疗均可采用传统的每日治疗方式(每周5次分割方案)或每周3次分割方案,治疗过程中无计划间隙。共有611例患者被分配接受治疗,其中9例因信息缺失而被排除在分析之外。患者于1976年1月至1985年12月入组试验,随访时间最长为10年,最短为3年。与长疗程治疗方案相比,短疗程治疗方案的总剂量有所降低。根据每周采用5次分割还是3次分割方案,总剂量的降低幅度在18%至22%之间。总体而言,试验的两组之间未发现具有统计学意义的差异。在短总治疗时间内接受每周5次分割治疗的患者,晚期正常组织效应较少。基于年龄、分期和解剖部位分层的分析显示,死亡的相对风险(短/长总治疗时间)为1.23,95%置信区间为0.96至1.59。按分期和部位分层的分析显示,局部复发/肿瘤持续存在的相对风险及其95%置信区间为1×10(0.84 - 1.44),喉切除术的相对风险及其95%置信区间为1.01(0.70 - 1.45)。